Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

741
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
741

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Macrophages de<i>liver</i> growth.

Science signaling·2025
Same author

Making sense of gastric cancer.

Science signaling·2025
Same author

Alarmin' lymphoid developments.

Science signaling·2025
Same author

In Science Journals.

Science (New York, N.Y.)·2025
Same author

Healing limited.

Science signaling·2024
Same author

Neurons go antiviral.

Science signaling·2024

Related Experiment Video

Updated: Oct 18, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.2K

Improving IL-2 for T cell therapy.

Amy E Baek1

  • 1Science Signaling, AAAS, Washington, DC 20005, USA.

Science Signaling
|October 5, 2021
PubMed
Summary

A novel interleukin-2 (IL-2) partial agonist was developed to boost T cell antitumor activity. This approach prevents T cell terminal differentiation, improving their cancer-fighting capabilities.

Area of Science:

  • Immunology
  • Cancer Biology
  • T cell therapy

Background:

  • Interleukin-2 (IL-2) is crucial for T cell function but has dose-limiting toxicities.
  • Full IL-2 agonism can lead to T cell exhaustion and terminal differentiation, limiting therapeutic efficacy.
  • Partial IL-2 agonism offers a potential strategy to enhance T cell responses while mitigating adverse effects.

Purpose of the Study:

  • To investigate the therapeutic potential of a novel IL-2 partial agonist.
  • To determine if partial IL-2 agonism can enhance T cell-mediated antitumor immunity.
  • To assess the impact of partial IL-2 agonism on T cell differentiation and function.

Main Methods:

  • Development and characterization of a novel IL-2 partial agonist.
  • In vitro assays to evaluate T cell proliferation, activation, and cytokine production.

More Related Videos

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.9K
Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes
12:47

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes

Published on: May 14, 2012

19.0K

Related Experiment Videos

Last Updated: Oct 18, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.2K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.9K
Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes
12:47

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes

Published on: May 14, 2012

19.0K
  • In vivo studies using tumor models to assess antitumor efficacy and T cell responses.

    • Main Results:

    • The IL-2 partial agonist selectively activated specific T cell subsets.
    • Partial agonism prevented the terminal differentiation of T cells, maintaining a more functional phenotype.
    • Enhanced T cell activity mediated by the partial agonist resulted in significant tumor growth inhibition.

    Conclusions:

    • Partial IL-2 agonism represents a promising strategy for improving T cell-based cancer immunotherapy.
    • Avoiding T cell terminal differentiation is key to enhancing sustained antitumor responses.
    • This approach may overcome limitations associated with conventional IL-2 therapy.